MitchellLShiffmanMD

Gastroenterology • Richmond, VA

Hepatology & Liver Transplantation

Director

Join to view full profile

Dr. Shiffman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shiffman's full profile

Already have an account?

Office
5855 Bremo Road
509
Richmond, VA 23226
Phone+1 804-977-8920

Education & Training

Virginia Commonwealth University Health SystemFellowship, Gastroenterology, 1986 - 1989
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 1983 - 1986
SUNY Upstate Medical UniversityClass of 1983

Certifications & Licensure

VA State Medical License 1984 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2003-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013

Clinical Trials

Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment Start of enrollment: 2000 Jun 01
Completed
Phase 3
Development of a Breath Test for Monitoring Patients With Liver Disease Start of enrollment: 2005 Sep 01
Completed
Phase 3
Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection Start of enrollment: 2002 May 01
Completed
Phase 3
Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C Start of enrollment: 2005 Nov 01
Completed
Not Applicable
BreathID Multi-center HCV Liver Breath Test Study Start of enrollment: 2006 Jul 01
Terminated
Phase 2
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics Start of enrollment: 2008 Sep 01
Terminated
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C Start of enrollment: 2007 Jul 01
Completed
Phase 2
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients Start of enrollment: 2008 Mar 01
Completed
Phase 2
A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Start of enrollment: 2013 Jan 01
Unknown status
Phase 4
Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis Start of enrollment: 2013 Aug 01
Completed
Phase 2
Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing Start of enrollment: 2014 Feb 01
Completed
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection Start of enrollment: 2014 Dec 09
Terminated
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis Start of enrollment: 2015 Jun 01
Completed
Phase 2
Study of Oral Treatments for Hepatitis C Start of enrollment: 2016 Jun 01
Completed
Phase 4
Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124 Start of enrollment: 2016 Jul 31
Withdrawn
Early Phase 1
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis Start of enrollment: 2020 Jun 22
Active, not recruiting
Phase 2, Phase 3
CM-101 in PSC Patients -The SPRING Study Start of enrollment: 2020 Oct 01
Active, not recruiting
Phase 2
Roles: Contact
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein Start of enrollment: 2023 Mar 06
Recruiting
Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

17 citations
Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steat...
Zobair M. Younossi, Maria Stepanova, Mazen Noureddin, Kris V. Kowdley, Simone I. Strasser
Hepatology Communications. 2021-05-12
51 citations
Liver and intestine transplantation: summary analysis, 1994-2003.
Douglas W. Hanto, Thomas M. Fishbein, C. Wright Pinson, Kim M. Olthoff, Mitchell L. Shiffman
American Journal of Transplantation. 2005-04-01
371 citations
SIMILARITIES AND DIFFERENCES IN OUTCOMES OF CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS AND HEPATITIS C
Arun J. Sanyal, Colin Banas, Carol Sargeant, Velimir A. Luketic, Richard K. Sterling
Hepatology. 2006-04-01

Journal Articles

Diagnosis and Management of Primary Biliary Cholangitis
Zobair M Younossi, Kris V Kowdley, Ira M Jacobson, Mitchell L Shiffman, Paul Kwo, Nature
Has Access to HCV Therapy Changed for Patients with Mental Health or Substance Use Disorders in the DAA Period?
Mamta K Jain, Mitchell L Shiffman, Hepatology
Response to Perrella Et Al
Paul Y Kwo, Mitchell L Shiffman, Nature
Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C)
Mitchell L Shiffman, Stephanie Noviello, Gregory D Huhn, Antiviral Therapy
Join now to see all

Lectures

Challenges in Hepatitis C Management: DAA Failures, Special Populations, and Controversies
AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/9/2018

Press Mentions

‘It’s Time for Action’: World Hepatitis Day Calls to End an ‘Entirely Preventable Disease’July 26th, 2024
The Impact of Curing HCV on the Liver and the Extra-Hepatic Manifestation of Chronic HCVSeptember 23rd, 2016
HCV Treatment Regimen Not Impacted by Acid-Reducing AgentsApril 7th, 2016

Grant Support

Ancillary Study To The HALT-C Anti-Viral Long-Term Treatment Against CirrhosiNational Center For Research Resources2009–2010
Clinical Trial: HEP C Antiviral Long-Term Treatment Against Cirrhosis (Halt-C)National Center For Research Resources2008–2009
Quantitative Assessment Of Hepatic Function In Chronic Hepatitis CNational Center For Research Resources2005–2008
HEP C Antiviral Long-Term Treatment Against Cirrhosis (Halt-C) TrialNational Center For Research Resources2005–2007
Natural History Of Chronic HEP B &C And The Effects Of Anti-Viral TherapyNational Center For Research Resources2004–2005
PEG Interferon PLUS Ribavirin For The Treatment Of HCVNational Center For Research Resources2004
HEP C Antiviral Long-Term Treatment Against CirrhosisNational Center For Research Resources2004
Assessment Of Hepatic Function In Chronic Hepatitis CNational Center For Research Resources2004
Tx Of Chronic Hepatitis C &Interferon PLUS Ribavirin &Treatment NANational Center For Research Resources1999–2001
Treatment Of Chronic Hepatitis C W/ Combination Of Interferon PLUSNational Center For Research Resources1999–2001
Randomized DBL Blind Placebo Contr Dose Escalation Study W/ VX 497 INational Center For Research Resources1999–2001
Prospective Randomized Controlled Trial To Determine IF Reduction InNational Center For Research Resources1999–2001
Mycophenolate Mofetil In Primary Sclerosing CholangitisNational Center For Research Resources1999–2001
Treatment Of Patients With Chronic Hepatitis C With A Combination Of InterferonNational Center For Research Resources1998–2001
Natural History, Prevention And Treatment Of Recurrent Viral Hepatitis B &CNational Center For Research Resources1998–2001
Evaluation Of GM-CSF For Treatment Of Chronic HCVNational Center For Research Resources1998–2001
Optimum Patient Population And Dosing Regimen For Treament Of Hepatitis CNational Center For Research Resources1997–2001
Metabolic Liver Function Test To Predict Morbidity/Mortality In Liver CirrhosisNational Center For Research Resources1997–2001
History Of Chronic Hepatitis C After Liver TransplantNational Center For Research Resources2000
Hepatitis C Clinical Trial- Clinical CentersNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2000
A Phase I/II Study Of Recombinant Human Inteleukin 12 For Chronic Hepatitis CNational Center For Research Resources1998–1999
Natural History, Prevention And TreatmentNational Center For Research Resources1997
Evaluation Of Granulocyte MacrophageNational Center For Research Resources1997
Escalating Doses Of Interferon A2B As A Way To Improve Response To InterferonNational Center For Research Resources1997
Combination Therapy Of Interferon A2B With Chcsf For Chronic Hepatitis CNational Center For Research Resources1997
Monoethylglycinexylide Formation--An Indicator Of Liver FunctionNational Center For Research Resources1996–1997
Chronic Hepatitis C And Granulocyte Macrophage Stimulating FactorNational Center For Research Resources1996–1997
Postoperative Care Of The Liver Transplant PatientNational Center For Research Resources1995–1997
Maintenance Therapy With Interferon A 2B For Patients With Chronic Hepatitis CNational Center For Research Resources1995–1997
Treatment Of Hepatitis C Virus Infection With Alpha InterferonNational Center For Research Resources1994–1997
Chronic Hepatitis C Treatment With Interferon And Ursodioxycholic AcidNational Center For Research Resources1994–1997
Treatment Of Chronic Hepatis B Virus Infection With Alpha InterferonNational Center For Research Resources1993–1997
Randomized Controlled Trial To Determine Efficacy Of Combination TherapyNational Center For Research Resources1996
UDCA And Bile Composition And Cyclosporine Absorption In Liver TransplantsNational Center For Research Resources1995–1996
Escalating Doses Of Interferon A-2b As A Way To Improve Response To InterferonNational Center For Research Resources1995–1996
Mucin Hypersecretion Effect On Gallbladder PhysiologyNational Institute Of Diabetes And Digestive And Kidney Diseases1994–1995
Escalating Doses Of Interferon-A-2b As A Way To Improve Response To InterferonNational Center For Research Resources1994
Post-Operative Care Of The Liver Transplant PatientNational Center For Research Resources1993–1994
Effect Of Mucin Hypersecretion On Gallbladder PhysiologyNational Institute Of Diabetes And Digestive And Kidney Diseases1991–1993

MitchellLShiffmanMD

Dr. Shiffman is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

Viewing the full profile is available to verified healthcare professionals only.